BAX
ACCE-researchedOverview
ACCE thesis
Baxter manufactures kidney dialysis machines, IV solutions, and hospital pharmaceuticals that keep critically ill patients alive in intensive care units worldwide. The company controls 37% of the global peritoneal dialysis market and operates the largest network of plasma collection centers in the United States, creating sticky revenue streams from patients who need these products indefinitely. Management expects the kidney care division to accelerate growth in 2024 after completing the separation of its biopharma business, which removes $3 billion in lower-margin revenue and allows focus on higher-return medical devices. Trading at 8.7x forward earnings despite generating $12.8 billion in annual revenue, the stock reflects excessive pessimism about a business that serves non-discretionary medical needs. The company's free cash flow jumped 47% in Q3 as supply chain disruptions from 2022-2023 finally resolved.
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
Price
Valuation
INVESTORSix independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.
- +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
- +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
- +Editable DCF workbench with saved scenarios
Quality
INVESTORThe full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.
- +Conviction score breakdown and earnings-quality grade
- +Growth / value / quality / momentum component scores
- +90-day score history and score-threshold backtests
Analysts
Wall Street consensus
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
- +Price-target low / average / high vs the current price, with implied upside
- +Forward revenue and EPS consensus by fiscal year
- +ACCE fair-value models lined up against the Street
Smart Money
PROFollow the institutions: 13F position changes, insider trades, and active 13D activist filings.
- +Quarter-over-quarter institutional position changes
- +Recent open-market insider transactions
- +Active 13D activist filings and top holders
Compare
Where it sits vs peers
Algorithmic peers (6)
| Ticker | Company | Mcap | P/E | ROE | D/E | Yield | Quality | |
|---|---|---|---|---|---|---|---|---|
| COO | The Cooper Companies Inc. Common Stock | $10.5B | 19.0 | 6.8% | 0.30 | 0.0% | - | Compare |
| AVTR | Avantor Inc. Common Stock | $10.5B | - | -9.7% | 0.71 | 0.0% | - | Compare |
| ALGN | Align Technology Inc. Common Stock | $10.5B | 25.6 | 10.2% | 0.01 | 0.0% | - | Compare |
| RGEN | Repligen Corporation Common Stock | $10.0B | 242.3 | 2.0% | 0.27 | 0.0% | - | Compare |
| COLO-B.CO | Coloplast A/S | $14.5B | 34.1 | 18.5% | 1.36 | 5.5% | - | Compare |
| FPH.AX | Fisher & Paykel Healthcare Corporation Limited | $14.8B | 55.0 | 23.4% | 0.03 | 1.5% | - | Compare |
Sector report card
Where BAX ranks against its sector peers on each metric.
News and Record
Press releases mentioning this company
- GlobeNewswire•Sep 7, 2026Drug Reconstitution Systems Market Trends, Shares and Growth Opportunities Worldwide 2026-2035 Featuring Profiles of Baxter, ICU Medical, B. Braun, Vetter Pharma, Nipro, SCHOTT-KAISHA
- Business Wire•Aug 19, 2026Baxter Appoints John Rogers Chief Financial Officer
- Business Wire•Aug 18, 2026Baxter Announces Pricing for Its Upsized Cash Tender Offers
Ask anything, Pro feature
Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.